全文获取类型
收费全文 | 103307篇 |
免费 | 13593篇 |
国内免费 | 3489篇 |
专业分类
耳鼻咽喉 | 394篇 |
儿科学 | 1376篇 |
妇产科学 | 1000篇 |
基础医学 | 4388篇 |
口腔科学 | 2887篇 |
临床医学 | 13625篇 |
内科学 | 8151篇 |
皮肤病学 | 1226篇 |
神经病学 | 3123篇 |
特种医学 | 1919篇 |
外国民族医学 | 12篇 |
外科学 | 7095篇 |
综合类 | 22779篇 |
现状与发展 | 14篇 |
一般理论 | 47篇 |
预防医学 | 8531篇 |
眼科学 | 1018篇 |
药学 | 12429篇 |
632篇 | |
中国医学 | 25852篇 |
肿瘤学 | 3891篇 |
出版年
2024年 | 277篇 |
2023年 | 2498篇 |
2022年 | 3504篇 |
2021年 | 5901篇 |
2020年 | 6647篇 |
2019年 | 4581篇 |
2018年 | 4114篇 |
2017年 | 5186篇 |
2016年 | 5086篇 |
2015年 | 4475篇 |
2014年 | 9266篇 |
2013年 | 8618篇 |
2012年 | 8066篇 |
2011年 | 8131篇 |
2010年 | 6529篇 |
2009年 | 5241篇 |
2008年 | 4665篇 |
2007年 | 4878篇 |
2006年 | 3972篇 |
2005年 | 3295篇 |
2004年 | 2686篇 |
2003年 | 2313篇 |
2002年 | 1791篇 |
2001年 | 1533篇 |
2000年 | 1218篇 |
1999年 | 929篇 |
1998年 | 695篇 |
1997年 | 624篇 |
1996年 | 481篇 |
1995年 | 434篇 |
1994年 | 418篇 |
1993年 | 288篇 |
1992年 | 309篇 |
1991年 | 266篇 |
1990年 | 206篇 |
1989年 | 193篇 |
1988年 | 174篇 |
1987年 | 155篇 |
1986年 | 111篇 |
1985年 | 130篇 |
1984年 | 107篇 |
1983年 | 56篇 |
1982年 | 65篇 |
1981年 | 63篇 |
1980年 | 58篇 |
1979年 | 33篇 |
1978年 | 19篇 |
1977年 | 24篇 |
1976年 | 22篇 |
1975年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
21.
22.
目的 对中医药治疗特发性肺纤维化(idiopathic pulmonary fibrosis, IPF)的系统评价(SRs)进行再评价。方法 检索知网、中国生物医学数据库、维普、万方、The Cochrane Library、Web of Science、PubMed和EMbase数据库,纳入中医药治疗IPF的SRs,截止2021年5月。使用AMSTAR 2量表进行方法学质量评价,GRADE系统工具进行结局指标证据质量分级。结果 共纳入28篇文献,试验组除辨证论治外,治疗方法集中在活血化瘀、补肺益气等方面,基本符合治疗法则。结果显示中医药治疗IPF可以提高有效率、增加肺功能、提高PaO2、增加6WMD、缓解临床症状、提高患者的生活质量等。AMSTAR 2量表评价,所纳入SRs均有多项关键条目不达标,整体方法学质量等级不高。采用GRADE工具进行质量分级,一共234个结局指标,无高等证据质量,整体证据等级不高。结论 中医药对比西医治疗IPF有效且不良反应不明显,但RCT研究和系统评价研究方法质量尚有缺陷,完全按照西医评价指标可能会低估真实结果,未来需要更规范的研究及适合中医的评价指标,对中医药研究的安全性方面关注还有待提高。 相似文献
23.
以“七麦数据”网站收录的中医移动医疗App作为研究对象,采用网络调查法和文献分析法,根据“七麦数据”对移动医疗App的分类,结合中医移动医疗App的信息服务内容和特点,将筛选出的中医移动医疗App划分为医疗健康类、中医养生类、知识传播类、全面综合类,并根据“七麦数据”网站中对各类中医移动医疗App的打分及累计下载量筛选出最具代表性的12款中医移动医疗App,从全面性、人性化、安全性、实用性4个一级指标和40个二级指标对其信息服务现状进行评价,指出当前中医移动医疗App信息服务存在的问题并提出建议。 相似文献
24.
25.
Steven P. Rowe MD PhD Martin G. Pomper MD PhD 《CA: a cancer journal for clinicians》2022,72(4):333-352
The authors define molecular imaging, according to the Society of Nuclear Medicine and Molecular Imaging, as the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems. Although practiced for many years clinically in nuclear medicine, expansion to other imaging modalities began roughly 25 years ago and has accelerated since. That acceleration derives from the continual appearance of new and highly relevant animal models of human disease, increasingly sensitive imaging devices, high-throughput methods to discover and optimize affinity agents to key cellular targets, new ways to manipulate genetic material, and expanded use of cloud computing. Greater interest by scientists in allied fields, such as chemistry, biomedical engineering, and immunology, as well as increased attention by the pharmaceutical industry, have likewise contributed to the boom in activity in recent years. Whereas researchers and clinicians have applied molecular imaging to a variety of physiologic processes and disease states, here, the authors focus on oncology, arguably where it has made its greatest impact. The main purpose of imaging in oncology is early detection to enable interception if not prevention of full-blown disease, such as the appearance of metastases. Because biochemical changes occur before changes in anatomy, molecular imaging—particularly when combined with liquid biopsy for screening purposes—promises especially early localization of disease for optimum management. Here, the authors introduce the ways and indications in which molecular imaging can be undertaken, the tools used and under development, and near-term challenges and opportunities in oncology. 相似文献
26.
27.
28.
《Mayo Clinic proceedings. Mayo Clinic》2022,97(8):1525-1533
The importance of the left atrial appendage (LAA) as the source of thromboembolism including stroke in patients with nonvalvular atrial fibrillation is well documented, with more than 90% of ischemic strokes related to a LAA thrombus. Although oral anticoagulation has been the standard of care, approximately 50% to 60% of patients either have contraindications to oral anticoagulation or do not continue the medication beyond the first year. This led to the development of local site-specific therapy to occlude the LAA by either surgical or transcatheter means. Despite marked advancements, incomplete LAA closure with surgical and transcatheter approaches remains frequent. The etiology of incomplete LAA closure and its clinical implications remain unclear. Multiple strategies are in development including changes in deployment techniques, a new device design, and alternative approaches to leak closure. 相似文献
29.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
30.
Bioimpedance as a measure of fluids in patients with septic shock. A prospective observational study
Janne Meisner Madsen Theis S. Itenov Ellen Bjerre Koch Morten H. Bestle 《Acta anaesthesiologica Scandinavica》2023,67(3):319-328